TAK-653 Powder

Description

TAK-653 Powder
CAS Number	1358751-06-0
Molar Mass	373.47 g/mol
Chemical Formula	C19H23N3O3S
IUPAC Name	9-[4-(cyclohexyloxy)phenyl]-7-methyl-3,4-dihydropyrazino[2,1-c][1,2,4]thiadiazine 2,2-dioxide

Introduction

TAK-653 Powder is a synthetic heterocyclic small molecule and AMPA receptor positive allosteric modulator, supplied strictly for laboratory and in vitro research use. It is studied by researchers investigating glutamatergic signaling, synaptic potentiation mechanisms, and downstream neurotrophic pathways. TAK-653 is not intended for human consumption, veterinary use, or any application outside of a controlled research setting.

Key Characteristics

TAK-653 Powder is manufactured to a high standard of chemical purity to support reproducible research outcomes. Each batch is formulated with attention to structural precision and lot-to-lot consistency, allowing researchers to rely on stable results across independent experiments.

Research Applications

TAK-653 is used in neuropharmacology research to investigate AMPA receptor potentiation with minimal intrinsic agonistic activity, a pharmacological profile distinct from earlier AMPA receptor potentiators. It serves as a mechanistic tool for probing how glutamate-dependent receptor modulation relates to synaptic transmission, cognitive performance, and neurotrophic signaling pathways in model systems and research participants.

Research Benefits

TAK-653 and AMPA Receptor Potentiation

Research indicates that TAK-653 binds the ligand-binding domain of the AMPA receptor in a glutamate-dependent manner, strictly potentiating glutamate-induced calcium influx through structural interference at a specific serine residue rather than acting as a direct agonist. Studies have investigated this mechanism in cell culture, primary neurons, and brain slices, finding that TAK-653 improved both working memory and recognition memory in animal models while maintaining a wide safety margin against convulsion.

TAK-653 and Neurotrophic Signaling

Studies propose that TAK-653 activates the mTOR and p70S6 kinase signaling pathway, along with their upstream regulators Akt and ERK, and increases brain-derived neurotrophic factor protein levels in cultured cortical neurons. Researchers use this model to explore how this signaling cascade relates to behavioral outcomes, with sub-chronic administration producing effects in a preclinical behavioral model without the hyperlocomotor response associated with NMDA receptor antagonist comparators.

TAK-653 and Central Nervous System Pharmacodynamics

Research suggests that TAK-653 produces measurable central nervous system effects in humans, including changes in saccadic peak velocity, adaptive tracking, and Stroop test performance. Studies have investigated this pharmacodynamic profile in a randomized, double-blind, placebo-controlled crossover trial using a standardized battery of neurophysiological and cognitive tests, finding a pattern consistent with increased cortical excitability previously reported using transcranial magnetic stimulation.

Summary

TAK-653 Powder is a synthetic heterocyclic small molecule supplied exclusively for laboratory research. It supports investigation into three distinct areas: AMPA receptor potentiation mechanisms, neurotrophic signaling, and central nervous system pharmacodynamics. As with all research compounds in this catalog, TAK-653 is intended strictly for research use and not for human or veterinary application.

Disclaimer

This content is presented exclusively for educational purposes and should not be construed as medical advice. THE MATERIALS REFERENCED HEREIN ARE EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH USE.

Any clinical research initiatives must be conducted under the guidance of the relevant Institutional Review Board (IRB). Similarly, preclinical research involving animals must comply with the directives of the Institutional Animal Care and Use Committee (IACUC), adhering to the standards delineated by the Animal Welfare Act (AWA).

Our informational content is meticulously designed for research-oriented insights and is not a substitute for individual analysis and verification from credible sources before any purchasing decisions are made.

Upon finalizing your order and payment, you explicitly acknowledge and agree to adhere to our Terms and Conditions. Customer contentment stands as our paramount concern. If you are dissatisfied with the product received, kindly contact us at 419-707-5450 or email our support team at support@bc9.co.

IMPORTANT NOTICE: All products showcased on our platform are EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH APPLICATIONS. They are expressly not intended for veterinary or human utilization.

References

1. Suzuki A, Kunugi A, Tajima Y, Suzuki N, Suzuki M, Toyofuku M, Kuno H, Sogabe S, Kosugi Y, Awasaki Y, Kaku T, Kimura H. Strictly regulated agonist-dependent activation of AMPA-R is the key characteristic of TAK-653 for robust synaptic responses and cognitive improvement. Sci Rep. 2021 Jul 15;11(1):14532. doi: 10.1038/s41598-021-93888-0. PMID: 34267258. Read More
2. Hara H, Suzuki A, Kunugi A, Tajima Y, Yamada R, Kimura H. TAK-653, an AMPA receptor potentiator with minimal agonistic activity, produces an antidepressant-like effect with a favorable safety profile in rats. Pharmacol Biochem Behav. 2021 Dec;211:173289. doi: 10.1016/j.pbb.2021.173289. PMID: 34655652. Read More
3. Dijkstra F, O’Donnell P, Klaassen E, Buhl D, Asgharnejad M, Rosen L, Zuiker R, van Gerven J, Jacobs G. Central nervous system effects of TAK-653, an investigational alpha-amino-3-hydroxy-5-methyl-4-isoxazole receptor (AMPAR) positive allosteric modulator in healthy volunteers. Transl Psychiatry. 2022 Sep 24;12(1):408. doi: 10.1038/s41398-022-02148-w. PMID: 36153330. Read More